Hot Trades in Pre-Market US Stocks
Recursion is up 9.13% in pre-market trading. Based on recent key news:
<ol>
<li>
On December 8, Recursion Pharmaceuticals announced the use of AI technology for drug development, which is expected to significantly shorten time and costs. This news has driven the stock price up, reflecting the market's positive response to innovative technology. Source: Reuters
</li>
<li>
On December 5, company director Blake Borgeson sold a large amount of stock, attracting market attention. Nevertheless, the stock price has maintained an upward trend, showing investors' confidence in the company's long-term prospects. Source: EDGAR
</li>
<li>
On December 6, CEO Christopher Gibson also sold shares, but the market's confidence in the company's AI technology seems to have offset this impact. Source: EDGAR AI technology is widely used in drug development, attracting market attention.
</li>
</ol>
Top Gainers in Pre-Market US Stocks
Cemtrex is up 302.28% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.
Treasure Gbl is up 125.90% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.
Biodexa Pharmaceuticals is up 96.43% in pre-market trading, with no significant news recently. Trading is active, and there is a clear flow of funds. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation

RXRX

Recursion Pharmaceuticals rose 9.13% in pre-market; Cemtrex rose 302.28% in pre-market; Treasure Gbl rose 125.90% in pre-market; Biodexa Pharmaceuticals rose 96.43% in pre-market

Tracking Unusual Activity

Recursion Pharmaceuticals

Pre-market hot trades in US stocks: AI technology aids drug development, Recursion rises 9.13% in pre-market, market confidence offsets the impact of executive sell-offs